SLC18A3 and Alzheimer disease: On the other hand, ginsenoside Re effectively enhanced the expression of ChAT and vesicular acetylcholine transporter (VAChT) in N2a cells, which in turn increased the production of ACh, thereby affecting the AD development process [179].